Rosuvastatin News and Research

RSS

Blood pressure and cholesterol lowering drugs do not negatively affect erectile function, study says

New study provides reassurance for men taking blood pressure and cholesterol modifying medications, reports the Canadian Journal of Cardiology.

29 Jan 2018

Common anti-cholesterol drugs show promise for reducing Alzheimer's disease risk

Common anti-cholesterol drugs show promise for reducing the risk of Alzheimer's disease, a University of Southern California-led study of Medicare data reveals.

14 Dec 2016

High-intensity statin treatments increase survival rates in patients with cardiovascular disease

A large national study has confirmed the value of high-intensity statin treatments for people with cardiovascular disease, according to researchers at the Stanford University School of Medicine.

9 Nov 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.

18 Jul 2016

Study shows short-term statin treatment does not benefit heart surgery patients

Giving daily doses of statins for a few days before and after heart surgery does not prevent heart muscle damage or the development of atrial fibrillation (AF), according to an international clinical trial led by the University of Oxford and funded by the British Heart Foundation.

5 May 2016

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets.

30 Apr 2016

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014.

31 Mar 2015

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Australian Prescriber publishes top 10 subsidised drugs in Australia

The annual publication of the top 10 subsidised drugs appears in the December edition of Australian Prescriber. Statins (cholesterol-lowering medicines) top the lists again.

1 Dec 2014

Rosuvastatin drug more effective among prediabetic patients, finds new study

Cardiovascular disease is the leading causes of death worldwide and high cholesterol plays a major role in accelerating its progression. Medical practitioners have turned to statins as a treatment to decrease cholesterol-carrying lipoproteins such as small dense lipoproteins (sdLDL), considered to be especially harmful.

19 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

21 Mar 2014

High-potency statins offer improved chance of survival in heart attack patients

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins.

20 Feb 2014

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.

23 Nov 2013

Simple blood test may predict people at highest risk for developing heart problems

For years, doctors have been divided on how effective annual testing and screenings are for apparently healthy individuals. New research, however, shows that a simple blood test may predict who is at highest risk to develop heart problems - and how long these people may have to live.

20 Nov 2013

Experimental agent fails to increase HDL levels, reveals new study

The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

5 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Study finds that high potency statins can beat dementia

Dr Lin said: "Statins are widely used in the older population to reduce the risk of cardiovascular disease. But recent reports of statin-associated cognitive impairment have led the US Food and Drug Administration (FDA) to list statin-induced cognitive changes, especially for the older population, in its safety communications."

2 Sep 2013

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Statins, a class of drugs used to lower cholesterol, are among the best selling drugs in North America and around the world. However, statin myopathy, which results in muscle pain and weakness, is a common side effect affecting up to 10 percent of statin users. A recent study led by Dr. Richard Kim of the Lawson Health Research Institute, in collaboration with Dr. Robert Hegele of Robarts Research Institute, and researchers from Vanderbilt University, found that commonly occurring genetic variations in a person's genes could put them at risk for statin-associated muscle injury.

7 Aug 2013